Hims & Hers Health (NYSE:HIMS) Stock Price Up 1.6% - Should You Buy?

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) rose 1.6% on Wednesday . The company traded as high as $52.33 and last traded at $49.74. Approximately 18,218,759 shares were traded during trading, a decline of 23% from the average session volume of 23,569,072 shares. The stock had previously closed at $48.96.

Analyst Ratings Changes

Several equities analysts have issued reports on HIMS shares. UBS Group set a $30.00 target price on Hims & Hers Health in a research note on Monday, June 23rd. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Bank of America upped their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $39.58.

Hims & Hers Health Stock Down 2.0%

The stock has a 50-day moving average of $53.26 and a 200 day moving average of $40.67. The stock has a market cap of $11.24 billion, a PE ratio of 72.80, a price-to-earnings-growth ratio of 1.88 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same quarter in the prior year, the business earned $0.05 earnings per share. The business's quarterly revenue was up 110.7% compared to the same quarter last year. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling

In related news, insider Michael Chi sold 17,102 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the completion of the transaction, the insider directly owned 278,654 shares in the company, valued at approximately $16,649,576.50. This trade represents a 5.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 23,107 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the sale, the chief financial officer directly owned 63,222 shares in the company, valued at $2,987,239.50. The trade was a 26.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 670,250 shares of company stock worth $34,487,591. Corporate insiders own 13.71% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Blume Capital Management Inc. increased its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter valued at approximately $30,000. Smartleaf Asset Management LLC raised its stake in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares during the period. Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $38,000. Finally, UMB Bank n.a. lifted its position in shares of Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after buying an additional 933 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.